Molecules, Vol. 24, Pages 2685: Long-Acting Injectable Statins —Is It Time for a Paradigm Shift?

Molecules, Vol. 24, Pages 2685: Long-Acting Injectable Statins—Is It Time for a Paradigm Shift? Molecules doi: 10.3390/molecules24152685 Authors: Lee M. Tatham Neill J. Liptrott Steve P. Rannard Andrew Owen In recent years, advances in pharmaceutical processing technologies have resulted in development of medicines that provide therapeutic pharmacokinetic exposure for a period ranging from weeks to months following a single parenteral administration. Benefits for adherence, dose and patient satisfaction have been witnessed across a range of indications from contraception to schizophrenia, with a range of long-acting medicines also in development for infectious diseases such as HIV. Existing drugs that have successfully been formulated as long-acting injectable formulations have long pharmacokinetic half-lives, low target plasma exposures, and low aqueous solubility. Of the statins that are clinically used currently, atorvastatin, rosuvastatin, and pitavastatin may have compatibility with this approach. The case for development of long-acting injectable statins is set out within this manuscript for this important class of life-saving drugs. An overview of some of the potential development and implementation challenges is also presented.
Source: Molecules - Category: Chemistry Authors: Tags: Opinion Source Type: research